LENZ Therapeutics (LENZ) Other Non-Current Liabilities (2020 - 2024)
LENZ Therapeutics (LENZ) posted quarterly Other Non-Current Liabilities of $64000.0 for Q3 2024, down 22.89% quarter-over-quarter from $83000.0 in Q2 2024.
LENZ Therapeutics (LENZ) Other Non-Current Liabilities (2020 - 2024) Analysis & Trends
LENZ Therapeutics (LENZ) has reported Other Non-Current Liabilities for 5 consecutive years, with $64000.0 the latest figure, recorded in Q3 2024.
- In Q3 2024, Other Non-Current Liabilities changed N/A year-over-year to $64000.0; the TTM figure through Sep 2024 stood at $64000.0 (changed N/A YoY), while the FY2023 annual figure was $121000.0, down 98.88% from the prior year.
- Other Non-Current Liabilities declined to $64000.0 in Q3 2024 per LENZ's latest filing, from $83000.0 in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $10.8 million in Q4 2022 and bottomed at $64000.0 in Q2 2021.
- Historically, Other Non-Current Liabilities has averaged $1.5 million across 5 years, with a median of $116000.0 in 2023.
- Annual changes were most pronounced in 2022 — Other Non-Current Liabilities jumped 3676.56% — and 2023, when it plunged 98.88%.
- LENZ Therapeutics' Other Non-Current Liabilities stood at $316000.0 in 2020, then tumbled by 79.75% to $64000.0 in 2021, then jumped by 16804.69% to $10.8 million in 2022, then slumped by 98.88% to $121000.0 in 2023, then slumped by 47.11% to $64000.0 in 2024.
- Business Quant data shows LENZ's Other Non-Current Liabilities at $64000.0 in Q3 2024, $83000.0 in Q2 2024, and $111000.0 in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | LENZ Therapeutics | 147.30 Mn | 147.30 Mn | 5.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 64,000.00 |
| Jun 30, 2024 | 83,000.00 |
| Mar 31, 2024 | 111,000.00 |
| Dec 31, 2023 | 121,000.00 |
| Mar 31, 2023 | 871,000.00 |
| Dec 31, 2022 | 10.82 Mn |
| Sep 30, 2022 | 2.42 Mn |
| Sep 30, 2021 | 64,000.00 |
| Jun 30, 2021 | 64,000.00 |
| Dec 31, 2020 | 316,000.00 |